Sabrina Mueller1, Thomas Wilke2, Benno Bechtel3, Yogesh Suresh Punekar4, Karen Mitzner5, J Christian Virchow6. 1. IPAM, University of Wismar, Alter Holzhafen 19, 23966 Wismar, Germany. Electronic address: kontakt@ipam-wismar.de. 2. IPAM, University of Wismar, Alter Holzhafen 19, 23966 Wismar, Germany. 3. GlaxoSmithKline, Canada. 4. GSK, Value Evidence and Outcomes, Brentford, TW8 9GS, UK. 5. Apotheke der Universitätsmedizin Rostock, Ernst-Heydemann-Straße 7, 18057 Rostock, Germany. 6. Universitätsmedizin Rostock, Abteilungen für Pneumologie/Interdisziplinäre Internistische Intensivstation, Ernst-Heydemann-Straße 6, 18057 Rostock, Germany.
Abstract
OBJECTIVES: The main objectives of this study, based on a large cohort of German COPD patients, were to assess the level of non-persistence (NP) and non-adherence (NA) with long-acting COPD inhaler treatment and to describe factors that may be associated with NP and NA. METHODS: This was a retrospective cohort analysis based on claims data provided by a German statutory health insurance fund (years 2010-2012). NP was analyzed for treatment-naïve patients only; it was defined as a gap of >90 days in medication availability. With regard to NA, first the overall yearly medication possession ratio (MPR) was analyzed, NA was defined as MPR<80%. Secondly, adherence was explored only for the period in which a patient continued therapy with a long-acting COPD agent (no gap>90 days). RESULTS: 45,937 COPD patients who received at least one prescription of any long-acting COPD agent were identified (mean age 71.4 years; 45.2% female). Among these, 22,276 (42.4%) were classified as newly treated. The percentage of NP patients after 12 months was 65.3% on an overall patient level. Agent-specific NP rates were: 58.5% for LABA, 47.9% for LAMA, 78.0% for ICS, and 69.4% for single-device LABA/ICS combination treatment. The overall 12-month MPR across all agent classes on a patient level was 57.9% (70.0% of patients classified as non-adherent). During periods of general treatment continuation, the mean MPR/NA rates were 85.0%/30.1% (patient level across all agents), 89.3%/28.2% (LABA), 92.1%/16.2% (LAMA), 84.2%/43.8% (ICS) and 84.1%/42.8% (LABA/ICS combination). In the Cox regression analyses, several factors like female gender, higher CCI or lower number of specialist' visits were associated with earlier discontinuation of therapy. In comparison to LABA therapy, LAMA therapy was less likely to be associated with early NP, whereas patients who initiated ICS therapy or a single-device LABA/ICS combination therapy faced a higher NP risk. CONCLUSIONS: In German COPD patients, persistence and adherence with respect to long-acting bronchodilator therapy is poor. Approximately two thirds of patients fail to continue treatment after 12 months. In addition, about one third implement their treatment poorly during periods of general therapy continuation.
OBJECTIVES: The main objectives of this study, based on a large cohort of German COPDpatients, were to assess the level of non-persistence (NP) and non-adherence (NA) with long-acting COPD inhaler treatment and to describe factors that may be associated with NP and NA. METHODS: This was a retrospective cohort analysis based on claims data provided by a German statutory health insurance fund (years 2010-2012). NP was analyzed for treatment-naïve patients only; it was defined as a gap of >90 days in medication availability. With regard to NA, first the overall yearly medication possession ratio (MPR) was analyzed, NA was defined as MPR<80%. Secondly, adherence was explored only for the period in which a patient continued therapy with a long-acting COPD agent (no gap>90 days). RESULTS: 45,937 COPDpatients who received at least one prescription of any long-acting COPD agent were identified (mean age 71.4 years; 45.2% female). Among these, 22,276 (42.4%) were classified as newly treated. The percentage of NP patients after 12 months was 65.3% on an overall patient level. Agent-specific NP rates were: 58.5% for LABA, 47.9% for LAMA, 78.0% for ICS, and 69.4% for single-device LABA/ICS combination treatment. The overall 12-month MPR across all agent classes on a patient level was 57.9% (70.0% of patients classified as non-adherent). During periods of general treatment continuation, the mean MPR/NA rates were 85.0%/30.1% (patient level across all agents), 89.3%/28.2% (LABA), 92.1%/16.2% (LAMA), 84.2%/43.8% (ICS) and 84.1%/42.8% (LABA/ICS combination). In the Cox regression analyses, several factors like female gender, higher CCI or lower number of specialist' visits were associated with earlier discontinuation of therapy. In comparison to LABA therapy, LAMA therapy was less likely to be associated with early NP, whereas patients who initiated ICS therapy or a single-device LABA/ICS combination therapy faced a higher NP risk. CONCLUSIONS: In German COPDpatients, persistence and adherence with respect to long-acting bronchodilator therapy is poor. Approximately two thirds of patients fail to continue treatment after 12 months. In addition, about one third implement their treatment poorly during periods of general therapy continuation.
Authors: Rachel Willard-Grace; Chris Chirinos; Jessica Wolf; Denise DeVore; Beatrice Huang; Danielle Hessler; Stephanie Tsao; George Su; David H Thom Journal: Ann Fam Med Date: 2020-01 Impact factor: 5.166
Authors: Jaco Voorham; Bernard Vrijens; Job Fm van Boven; Dermot Ryan; Marc Miravitlles; Lisa M Law; David B Price Journal: Pragmat Obs Res Date: 2017-04-18
Authors: Lindsay G S Bengtson; Michael DePietro; Jeffrey McPheeters; Kathleen M Fox Journal: Ther Adv Respir Dis Date: 2018 Jan-Dec Impact factor: 4.031
Authors: Michael Bogart; Richard H Stanford; François Laliberté; Guillaume Germain; Jennifer W Wu; Mei Sheng Duh Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-02-19
Authors: Hamid Tavakoli; Kate M Johnson; J Mark FitzGerald; Don D Sin; Andrea S Gershon; Tetyana Kendzerska; Mohsen Sadatsafavi Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-09-03
Authors: Faustine Dalon; Nicolas Roche; Manon Belhassen; Maëva Nolin; Hervé Pegliasco; Gaëtan Deslée; Bruno Housset; Philippe Devillier; Eric Van Ganse Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-08-20